Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ BTBD1 Polyclonal Antibody
Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA540899
Description
Peptide sequence: LPLQREPLYN WQATKASLKE RFAFLFNSEL LSDVRFVLGK GRGAAAAGGP Sequence homology: Cow: 100%; Guinea Pig: 100%; Human: 100%; Mouse: 100%; Rat: 100%.
The C-terminus of BTBD1 binds topoisomerase I. The N-terminus contains a proline-rich region and a BTB/POZ domain (broad-complex, Tramtrack and bric a brac/Pox virus and Zinc finger), both of which are typically involved in protein-protein interactions. Subcellularly, the protein localizes to cytoplasmic bodies. The C-terminus of the protein encoded by this gene binds topoisomerase I. The N-terminus contains a proline-rich region and a BTB/POZ domain (broad-complex, Tramtrack and bric a brac/Pox virus and Zinc finger), both of which are typically involved in protein-protein interactions. Subcellularly, the protein localizes to cytoplasmic bodies. Alternative splicing results in multiple transcript variants encoding different isoforms.
Specifications
BTBD1 | |
Polyclonal | |
Unconjugated | |
BTBD1 | |
1190005H08Rik; BTB (POZ) domain containing 1; BTB domain containing 1; BTB/POZ domain-containing protein 1; Btbd1; C15orf1; glucose signal-repressing protein; Gsrp; HCV NS5A-transactivated protein 8; hepatitis C virus NS5A-transactivated protein 8; NS5ATP8 | |
Rabbit | |
Affinity chromatography | |
RUO | |
53339 | |
-20°C, Avoid Freeze/Thaw Cycles | |
Liquid |
Western Blot | |
0.5 mg/mL | |
PBS with 2% sucrose and 0.09% sodium azide | |
Q9H0C5 | |
BTBD1 | |
Synthetic peptide directed towards the N-terminal of human BTBD1 (aa 38-87). | |
100 μL | |
Primary | |
Human | |
Antibody | |
IgG |
Safety and Handling
WARNING: Cancer - www.P65Warnings.ca.gov
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction